Sygnature Discovery Limited
Michael Kelly currently serves as the Director of Private Equity at Five Arrows Principal Investments since September 2016. In addition to this role, Michael holds positions as a Non-Executive Director at Sygnature Discovery and Everway, as well as a Board Observer for Juvare, Solifi, Centric Health, Voogd & Voogd Verzekeringen, and Karnov Group AB. Prior to these roles, Michael was an Investment Banking Associate at Greenhill & Co. from July 2011 to September 2016, following a summer internship with the firm in 2010. Michael earned a BSc in Economics from UCL between 2008 and 2011 and attended George Watson's College from 2002 to 2008.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Sygnature Discovery Limited
2 followers
Sygnature Discovery are a leading drug discovery CRO with expertise across a range of therapeutic and biological target classes. An expert partner in disciplines including Medicinal and Computational Chemistry, In Vitro and In Vivo Pharmacology, DMPK, supported by informatics.